MARIA CLEMENTINE MARTIN KLOSTERFRAU VERTRIEBSGESELLSCHAFT MBH
发明人:
VESTWEBER, ANNA-MARIA,GALÁN SOÚSA, JOSÉ,UNKAUF, MARKUS,PLOCH, MICHAEL
申请号：
RSP20160644
公开号：
RS54961B1
申请日:
2013.08.05
申请国别(地区):
RS
年份:
2016
代理人:
摘要：
Composition in a solid or liquid form, preferably solid dosage form, comprises: (a) 0.1-40 wt.%, preferably 3-18 wt.% at least one polysaccharide, preferably a virustatic and/or antiviral polysaccharide； (b) 0.001-5 wt.%, preferably 0.05-0.5 wt.% at least a surface disinfectant； and (c) 0.01-10 wt.%, preferably 0.1-2 wt.% optionally at least one acidic glycosaminoglycan or its salts or derivatives, preferably hyaluronic acid or its salts； (d) 0.01-5 wt.%, preferably 0.1-1 wt.% optionally at least one local anesthetic. ACTIVITY : Antiinflammatory. The antiinflammatory activity of the composition was tested in patients (18-75 years old) with inflammatory diseases of the ear and throat by administering composition (lozenge tablet containing 0.25 wt.% glycerin, 10 wt.% carrageenan, 0.25 wt.% polyhexanide, 77.41 wt.% matrix former, 11.75 wt.% carrier substance, and 0.34 wt.% flavored component) for 3 days. The result showed that the lozenge tablet exhibited reduction of inflammation (1.8) (according to the school grading system), compared to the tablets (mono preparation of active ingredients) (3.0). MECHANISM OF ACTION : None given.
